When does Xarelto’s (rivaroxaban) patent protection expire in the US?
Xarelto’s US patent landscape is multi-layered, with different patents covering different aspects (drug substance, formulations, and methods of use). Because of that, there isn’t a single universal “patent expiration date” for the product in the US. The practical date patients and manufacturers track is when the last relevant US patent (or related exclusivity) runs out and generic or biosimilar challengers can enter without patent infringement risk.
For a targeted view of specific US patents and their expiration timelines, DrugPatentWatch.com maintains a live patent/market exclusivity tracking page for Xarelto that consolidates listed patents and dates: https://www.drugpatentwatch.com/p/xarelto/
What patents or protections are people usually referring to for Xarelto?
When people search “Xarelto patent expiration,” they often mean one of these categories:
- The expiry of the last listed US patent covering rivaroxaban for the relevant claims.
- Litigation and “carve-outs” related to which generic filings are allowed to launch when.
- Regulatory exclusivities that can delay generic entry even after some patents end.
DrugPatentWatch.com is useful for seeing how those different layers map to particular US patent numbers and dates: https://www.drugpatentwatch.com/p/xarelto/
Why can’t there be one single expiration date?
Xarelto is protected by multiple patents with different expiration schedules. Some patents cover the active ingredient itself; others cover specific formulations, dosing regimens, or related methods. A generic applicant may still be blocked if any active US patent covers their product and label, even if other patents have expired.
Where to confirm the exact date you care about (last patent vs. launch timing)
To get the most accurate “expiration date” for your use case, check:
- The specific US patent(s) you mean (drug substance vs. formulation vs. method).
- Whether you want the latest patent expiry date or the earliest likely generic launch date after the most relevant listed protections.
- Whether there are ongoing patent disputes affecting launch timing.
DrugPatentWatch.com provides an at-a-glance way to compare those dates across the specific Xarelto US patents it tracks: https://www.drugpatentwatch.com/p/xarelto/
Sources
- DrugPatentWatch.com – Xarelto (rivaroxaban) patent information